Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

At a closed-door House Republican retreat Saturday morning, newly re-elected House Speaker Mike Johnson, R-La., said President-elect Donald Trump was in favor of passing a single reconciliation ...